Related Experiment Video
Updated: Oct 26, 2025
08:21
Cell-Free Dot Blot as a Practical and Adaptable Immunoassay Platform for the Detection of Antibody Response in Human and Animal Sera
Published on: May 23, 2025
592
Catalytic Clusterbody for Enhanced Quantitative Protein Immunoblot
Jiaojiao Li1, Xiangchun Zhang2, Fuping Gao3
1Department of Chemistry and Biology, Faculty of Environment and Life Science, Beijing University of Technology, Beijing 100124, China.
Analytical Chemistry
|July 30, 2021
Summary
Researchers developed novel clusterbodies, artificial catalytic antibodies, for highly sensitive detection of low-abundance protein biomarkers. This breakthrough enables earlier and more accurate tumor malignancy assessment.
Area of Science:
- Biochemistry
- Nanotechnology
- Biomarker Discovery
Background:
- Traditional antibodies face limitations in detecting low-abundance protein biomarkers crucial for tumor progression.
- Developing highly sensitive and accurate detection methods is essential for early cancer diagnosis and malignancy assessment.
Purpose of the Study:
- To develop and validate a novel artificial antibody platform, termed clusterbodies, for sensitive detection of low-abundance protein biomarkers.
- To establish a quantitative assay utilizing clusterbodies for improved accuracy and sensitivity in biomarker detection.
- To demonstrate the potential of clusterbodies in assessing tumor malignancy through biomarker expression analysis.
Main Methods:
- Artificial catalytic antibodies (clusterbodies) were engineered using metal clusters and peptides.
- Clusterbodies were characterized for their size, fluorescence, and catalytic/recognition properties.
- A quantitative assay was developed measuring clusterbody fluorescence and chemiluminescence upon biomarker binding.
- Assay reliability was validated against immunoblotting and enzyme-linked immunosorbent assay (ELISA).
Main Results:
- Clusterbodies exhibit ultrasmall size, intrinsic fluorescence, and enzyme-like catalytic properties.
- A quantitative assay using clusterbodies achieved high accuracy and sensitivity, validated by immunoblotting and ELISA.
- The detection limit for the target protein was as low as 1.0 pg, significantly lower than conventional immunoassays.
- Variations in biomarker expression levels correlated with tumor cell invasion ability.
Conclusions:
- Clusterbodies offer a powerful platform for sensitive detection of low-abundance protein biomarkers.
- This technology has potential applications in early-stage tumor malignancy assessment and complex biological matrix analysis.
- Clusterbody-based bioprobes can be engineered for advanced quantitative biosensing with customized functions.
